Testing treatment for severe inflammation in very ill adults
Part of Blood & lymphatic clinical trials.
This trial looks at how to treat a severe, whole-body immune overreaction (“hemophagocytosis”) in adults who are critically ill. You might be considered if blood counts are low (white blood cells and platelets) and if you are already receiving a growth-factor medicine (rhG-CSF).
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be over 18 years old
- Be critically ill and currently in intensive care-level condition
- Have low white blood cells (leukopenia) and low platelets (thrombocytopenia)
- Be receiving rhG-CSF (a medication that helps white blood cell recovery)
- You must not have a life expectancy under 24 hours
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy (SGX-001) for chronic granulomatous disease caused by a specific genetic change. The treatment tries to fix the gene in your immune cells so they can fight infections better, and the trial will follow participants for up to 15 years to make sure it's safe and effective.
This trial studies whether giving high-dose cyclophosphamide as an initial treatment works better for adults with HLH. HLH is a serious, overactive immune condition, and the study aims to improve control of the illness and safety.
This study follows adults who have findings that suggest HLH, a serious immune problem. It may help doctors better understand the condition by tracking patients over time and comparing symptoms and test results.
This trial tests a new combination of medicines (the GO regimen) for people with hemophagocytic lymphohistiocytosis (HLH) that is either newly diagnosed, has come back, or hasn't responded to other treatments. It aims to see if this approach can help when a stem cell transplant isn't an option right now.
This trial tests whether a short course of two medicines, dexamethasone (a steroid) and intravenous immunoglobulin (antibodies from donated blood), can help treat a rare condition called hemophagocytic lymphohistiocytosis (HLH) that is triggered by an infection. It may help control the body's overactive immune response and improve organ function.
This trial tests a combination of two drugs, emapalumab and ruxolitinib, for people with hemophagocytic lymphohistiocytosis (HLH), a rare condition where the immune system becomes overactive and damages organs. The goal is to control the disease with fewer side effects than standard treatments.
Hear when a new Hemophagocytosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.